30
Views
5
CrossRef citations to date
0
Altmetric
Review

Novel pharmacological targets and progression of new antitussive drugs

, &
Pages 1501-1512 | Published online: 02 Mar 2005

Bibliography

  • CHERRY DK, WOODWELL DA: National Ambulatory Medical Care Survey 2000 Summary. Adv. Data from Vital and Health Statistics (2002) 328:1–32.
  • MORICE AH: Epidemiology of cough. Pulmon. Pharm. Ther. (2002) 15:253–259.
  • MORICE AH: Epidemiology of chronic cough. Eur: Respic Rev (2002) 85:222–225.
  • BRAMAN SS, CARRAO WM: Cough: differential diagnosis and treatment. Clin. Chest Med. (1987) 8:177–182.
  • FULLER RW: Physiology and treatment of cough. Thorax (1990) 45:425–430.
  • LINDGREN BR, ANDERSSON RG: Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review. Med. Toxicol. Adverse Drug Exp. (1989) 4:369–380.
  • IRWIN RS, RICHTER JE: Gastroesophageal reflux and cough. Am. J. Gastroenterol (2000) 95:S9–S14.
  • NOVITSKY YVV, ZAWACKI JK, IRWIN RS, FRENCH CT, HUSSEY VM, CALLERY MP: Chronic cough due to gastroesophageal reflux disease: efficacy of antireflux surgery. Surg. Endoscop. (2002) 16:567–71.
  • FRENCH CT, IRWIN RS, FLETCHER KE, ADAMS TM: Evaluation of a cough-specific quality-of-life questionnaire. Chest (2002) 121:1123–1131.
  • IRWIN RS, FRENCH CT, FLETCHER KE: Quality of life in coughers. Puhnon. Pharm. The]: (2002) 15:283–286.
  • •Discusses impact of cough on the quality of life.
  • BANNER AS: Cough: physiology, evaluationand treatment. Lung (1986) 164:79–92.
  • CHOUDRY NB, FULLER RW: Sensitivity of the cough reflex in patients with chronic cough. Ear. Respic .1. (1992) 5:296–300.
  • WIDDICOMBE JG: Sensory neurophysiology of the cough reflex. J. Allergy Clin. Immunol (1996) 98:S84–S90.
  • WIDDICOMBE JG: Neurophysiology ofthe cough reflex. Ear. Respic J. (1998) 8:1193–1202.
  • WIDDICOMBE JG: Neuroregulation of cough: implications for drug therapy. Carr. Opinion Pharmacol. (2002) 2:256–263.
  • ••Review of the neuroregulation of coughwith insights into novel antitussive targets.
  • HEY JA, SHIH N-Y: Recent developments in antitussive therapy. Ann. Rep. Med. Chem. (2000) 36:53–62.
  • •Discusses new potential antitussive agents.
  • UNDEM BJ, CARR MJ, KOLLARIK M: Physiology and plasticity of putative cough fibers in the guinea pig. Pulmon. Pharm. The]: (2002) 15:193–198.
  • SHANNON R, MORRIS KF, LINDSEY BG: Ventrolateral medullary respiratory network and a model of cough motor pattern generation. J. Appl. PhysioL (1998) 84:2020–2035.
  • BOLSER DC, DAVENPORT PW: Functional organization of the central cough generation mechanism. Pulmon. Pharm. Ther. (2002) 15:221–225.
  • KARLSSON JA, LANNER AS, PERSSON CG: Airway opioid receptors mediate inhibition of cough and reflex bronchoconstriction in guinea-pigs. Pharmacol. Exp. Ther. (1990) 252:863–868.
  • ADOCK JJ: Peripheral opioid receptors and the cough reflex. Resp. Med (1991) 85:43–46.
  • CALLAWAY JK, KING RG, BOURA AL: Evidence for peripheral mechanisms mediating the antitussive actions of opioids in the guinea pig. Gen. Pharmacol (1991) 22:1103–1108.
  • REISINE T, PASTERNAK G: Opioid analgesics and antagonists. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics. JG Hardman, LE Limbird (Eds), McGraw-Hill, New York, USA (1996):521–555.
  • CHAU Ti CARTER FE, HARRIS LS: Antitussive effect of the optical isomers of p-, lc- and cs-opiate agonists/antagonists in the cat. Pharmacol Exp. The]: (1983) 226:108–113.
  • KAMEI J, TANIHARA H, KASUYA Y: Antitussive effects of two specific lc-opioid agonists, U-50488H and U-62066E, in rats. Ear. Pharmacol. (1990) 187:281–286.
  • KOTZER CJ, HAY DWP, DONDIO G, GIARDINIA G, PETRILLO P, UNDERWOOD DC: The antitussive activity of the 8-opioid receptor stimulation in guinea-pigs. j. Pharmacol. Exp. Ther: (2000) 292:803–809.
  • •Antitussive profile of the selective DOP opioid receptor agonist, SB-227122.
  • KAMEI J, IWAMOTO Y, SUZUKI T, NAGASE H, MISAWA M, KASUYA Y: Differential modulation of p-opioid receptor-mediated antitussive activity by 8-opioid receptor agonists in mice. Eur: .1. Pharmacol. (1993) 234:117–120.
  • KAMEI J, IWAMOTO Y, SUZUKI T, MISAWA M, NAGASE H, KASUYA Y: Involvement of 8 1-opioid receptor antagonism in the antitussive effect of 8-opioid receptor antagonists. Eur: Pharmacol. (1994) 251:291–294.
  • KAMEI J: 8-Opioid receptor antagonists as a new concept for central-acting antitussive drugs. Pulmon. Pharm. The]: (2002) 15:235–240.
  • WATLING KJ: Opioid receptors. In: The Sigma-RBI Handbook of Receptor Classification and Signal Transduction. KJ Watling (Ed.), Sigma-RBI, Natick, MA, USA (2001).
  • BELVISI MG, BOLSER DC: Summary: animal models for cough. Pulmon. Pharm. Ther. (2002) 15:249–250.
  • MEUNIER J-C, MOLLEREAU C, TOLL C et al.: Isolation and structure of the endogenous agonist of opioid receptor-like ORLi receptor. Nature (1995) 377:532–535.
  • CALO G, RIZZI A, BIGONI R, GUERRINI R, SALVADORI S, REGOLI D: Pharmacological profile of nociceptin/orphanin FQ receptors. Clin. Exp. Phannacol Physiol (2002) 29:223–228.
  • CALO G, GUERRINI R, RIZZI A, SALVADORI S, REGOLI D: Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br: J. Pharmacol (2000) 129:1261–1283.
  • GIULIANI S, LECCI A, MAGGI CA: Nociceptin and neurotransmitter release in the periphery. Peptides (2000) 21:977–984.
  • FISHER A, FORSSMAN WG, UNDEM BJ: Nociceptin-induced inhibition of tachykinergic neurotransmission in guinea pig bronchus. .1. Pharmacol Exp. Ther. (1998) 268:85–89.
  • PATEL HJ, GYEMBICZ MA, SPICUZZA L, BARNES PJ, BELVISI MG: Naloxone-insensitive inhibition of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by the novel opioid, nociceptin. Br: J. Pharmacol (1997) 120:735–736.
  • SHAH S, PAGE CP, SPINA D: Nociceptin inhibits non-adrenergic non-cholinergic contraction in guinea-pig airway. Br. .1. Pharmacol (1998) 125:510–516.
  • CORBOZ MR, RIVELLI MA, EGAN R et al.: Nociceptin inhibits capsaicin-induced bronchoconstriction in the isolated guinea-pig lung. Ear: Pharmacol (2000) 402:171–179.
  • CORBOZ MR, FERNANDEZ X, EGAN RW, HEY JA: Inhibitory activity of nociceptin/orphanin FQ on capsaicin-induced bronchoconstriction in the guinea pig. Life Sci. (2001) 69:1203–1211.
  • MCLEOD RL, PARRA LE, MUTTER JC et al.: Nociceptin inhibits cough in the guinea pig by activation of ORLi receptors. Br.Pharmacol (2001) 132:1175–1178.
  • •Antitussive characterisation of nociceptin in the guinea-pig.
  • MCLEOD RL, BOLSER DC, JIA Y et al.: Antitussive effect of nociceptin/orphanin FQ in experimental cough models. Pulmon. Pharm. The]: (2002) 15:213–216.
  • JIA Y, WANG X, APONTE SI et al.: Nociceptin inhibits capsaicin-induced guinea pig airway contraction through an inward-rectifier potassium channel. Br.Pharmacol (2002) 135:764–770.
  • RONZONI S, PERETTO I, GIARDINA GA: Lead generation and lead optimization approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists. Expert Opin. Ther. Patents (2001) 11:5625–5646.
  • DAUTZENBERG FM, WICHMANN J, HIGELIN J et al: Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist RO-646198: rapid and reversible desensitization of the ORLI receptor M vitro and lack of tolerance in vivo. Phannacol Exp. The]: (2001) 298:812–819.
  • HASHIBA E, LAMBERT DG, JENCK F, WICHMANN J, SMITH G: Characterization of the non-peptide nociceptin receptor agonist, RO-646198 in the Chinese hamster ovary cells expressing recombinant human nociceptin receptors. Life Sci. (2002) 70:1719–1725.
  • BROWN C, FEZOUI M, CONNELL SP, DE RYCK M, SELIG WM, ELLIS JL: Aerosol administration of the ORLi agonists nociceptin and RO-646198 inhibits citric acid-induced cough in guinea-pigs.Arn. Res Crit. Care Med. (2003) 167:A149.
  • BORMANN J, FEIGENSPAN A: GABAc receptors. Trends Neurosci (1995) 18:515–519.
  • MEHTA AK, TICKU MK: An update on GABAA receptors. Brain Res. Rev (1999) 29:196–217.
  • BOWERY NG, ENNA SJ: y-Aminobutyricacid (B) receptors: first of the functional metabotropic heterodimers. Pharmacol Exp. Ther. (2000) 292:2–7.
  • NOSALOVA G, VARONOS D, PAPADOPOULOU-DAIFOTIS Z, VISNOVSKY P, STRAPKOVA A: GABAergic mechanisms in the central control of cough. Acta Physiol Hung. (1987) 70:189–194.
  • NOSALOVA G: Actions of drugs affectingthe cough reflex. Bratisl Lek. Listy (1998) 10:531–535.
  • BELVISI MG, ICHINOSE M, BARNES PJ: Modulation of non-adrenergic, non-cholinergic neural bronchoconstriction in the guinea-pig airways via GABAB receptors. &J. Phannacol (1989) 97:1225–1231.
  • CHAPMAN RW, DANKO G, RIZZO CA, EGAN RW, MAUSER PJ, KREUTNER W: Prejunctional GABAB inhibition of cholinergic, neurally mediated airway contractions in guinea-pigs. Pulmon. Pharmacol (1991) 4:218–224.
  • CHAPMAN RW, DANKO G, DEL PRADO M et al.: Further evidence for prejunctional GABAB inhibition of cholinergic and peptidergic bronchoconstriction in guinea-pigs: studies with new agonists and antagonists. Pharmacol (1993) 46:314–323.
  • DANKO G, HEY JA, DEL PRADO M, KREUTNER W, CHAPMAN RW: GABAB inhibition of peptidergic airway microvascular leakage in guinea-pigs. Pharmacol Commun. 1:203–209.
  • BOLSER DC, AZIZ SM, DEGENNARO FC etal.: Antitussive effect of GABAB agonist in the cat and guinea pig. Br. .1. Pharmacol (1993) 110:491–495.
  • BOLSER DC, DEGENNARO FC, O'REILLY S, CHAPMAN RW, KREUTNER W, HEY JA: Peripheral and central sites of action of GABAB agonists to inhibit the cough reflex in the cat and guinea pig. Br. Pharmacol (1994) 113:1344–1348.
  • LALLEY PM: Biphasic effects of baclofen on phrenic motoneurons: possible involvement of two types of y-aminobutyric acid (GABA) receptors. Pharmacol Exp. Ther. (1983) 226:616–645.
  • DEFEUDIS FV: GABA and respiratory function. Gen. Pharmacol (1984) 12:441–443.
  • HEY JA, MINGO G, BOLSER DC, KREUTNER W, KROBATSCH D, CHAPMAN RW: Respiratory effects of baclofen and 3-aminopropylphosphinic acid in guinea-pigs. Br. .1. Pharmacol (1995) 114:735–738.
  • DICPINIGAITIS PV, DOBKIN JB: Antitussive effect of the GABA agonist baclofen. Chest (1997) 111:996–999.
  • DICPINIGAITIS PV, DOBKIN JB, RAUF K, ALDRICH TK: Inhibition of capsaicin-induced cough by 7-amino butyric acid agonist baclofen. Clin. Pharmacol (1998) 38:364–367.
  • DICPINIGAITIS PV: Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors. Ann. Pharmacother. (1996) 30:1242–1245.
  • DICPINIGAITIS PV, GRIMM DR, LESSER M: Baclofen-induced cough suppression in cervical spinal cord injury. Arch. Phys. Med. Rehab. (2000) 81:921–923.
  • GUNTHORPE MJ, BENHAM CD, RANDALL A, DAVIS JB: The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol Sci. (2002) 23:183–191.
  • MICHAEL GJ, PRIESTLEY JV: Differential expression of the mRNA for the vanilloid receptor subtype 1 in cells of the adult rat dorsal root and nodose ganglia and its down regulation by axotomy. Neurosci. (1999) 19:1844–1854.
  • TUCKER RC, KAGAYA M, PAGE CP, SPINA D: The endogenous cannabinoid agonist, anandamide stimulates sensory nerves in guinea-pig airways. Br. J. Pharmacol (2001) 132:1127–1135.
  • JIA Y, MCLEOD RL, WANG X, PARRA L, EGAN RW, HEY JA: Anandamide induces cough in conscious guinea pig through VR1 receptors. Br. J. Pharmacol (2002) 137:831–836.
  • DEVANE WA, HANUS L, BREUER A et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946–1949.
  • PRIMKUMAR LS, AHERN GP: Induction of vanilloid receptor channel activity by protein kinase C. Nature (2000) 408:985–990.
  • VELLANI V, MAPPLEBECK S, MORIONDO A, DAVIS JB, MCNAUGHTON PA: Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. PhysioL (2001) 534:813–825.
  • O'CONNELL F, THOMAS VE, STUDHAM JM, PRIDE NB, FULLER RW: Capsaicin cough sensitivity increases during upper respiratory infection. Resp. Med. (1996) 90:279–286.
  • DOHERTY MJ, MISTER R, PEARSON MG, CALVERLEY PMA: capsaicin responsiveness and cough in asthma and chronic obstructive pulmonary disease. Thorax (2000) 55:643–649.
  • MCLEOD RL, JIA Y, FERNANDEZ X et al.: Sulfur-dioxide exposure increases capsaicin-induced Ca2+ response in isolated nodose ganglia cells and induces cough hyperresponsiveness in guinea-pigs. Am J. Res. Grit. Care Med (2003) 167:A150.
  • MAGGI CA, PATACCHINI R, ROVERO P, GIACHETTI A: Tachykinin receptors and tachykinin receptor antagonists. Auton. Pharmacol (1993) 13:23–93.
  • CHAPMAN RW, HEY JA, MCLEOD R, MINNICOZZI M, RIZZO C: Tachykinins in the lungs. Drug News Perspect. (1998) 11:480–489.
  • BOLSER DC, DEGENNARO FC, O'REILLY S, MCLEOD RL, HEY JA: Central antitussive activity of the NKI. and NK2 tachykinin receptor antagonists, CP-99994 and SR-48968, in the guinea-pig and cat. Br. Pharmacol (1997) 121:165–170.
  • DAOUI S, COGNON C, NALINE E, EMONDS-ALT X, ADVENIER C: Involvement of tachykinin NK3 receptors in citric acid-induced cough and bronchial responses in guinea-pigs. Am. I Respic Crit. Care Med (1998) 158:42–48.
  • ANTHES JC, CHAPMAN RW, RICHARD C et al: SCH-206272: a potent, orally active tachykinin NK1, NK2 and NK3 receptor antagonist. Eut: Pharmacol (2002) 450:191–202.
  • SEKIZAWA K, JIA YX, EBIHARA T, HIROSE Y, HIRAYAMA Y, SASAKI H: Role of substance P in cough. Palm. Pharmacol (1996) 9:323–328.
  • MYERS AC, UNDEM BJ: Electrophysiological effects of tachykinins and capsaicin on guinea-pig bronchial parasympathetic ganglion neurons. Physiol (1993) 470:665–679.
  • HEY JA, DANKO G, DEL PRADO M, CHAPMAN RW: Augmentation of neurally evoked cholinergic bronchoconstrictor responses by prejunctional NK2 receptors in the guinea-pig. I Autonom. Pharmacol (1996) 16:41–48.
  • BABE KS, SERAFIN WE: Autacoids: Drug therapy of inflammation. In: Goodman and Cilman's The Pharmacological Basis of Therapeutics (9th edn). JG Hardman, LE Limbird, PB Molinoff, RW Ruddon, AG Gilman (Eds), McGraw-Hill, New York, USA (1996):581–600.
  • REGOLI D, BARABF J: Pharmacology of bradykinin and related kinins. Pharmacol Rev (1980) 32:1–46.
  • BARNES PJ, PAGE CP, CHUNG KF: Inflammatory mediators and asthma. Pharmacol Rev (1988) 40:49–84.
  • ELLIS KM, FOZARD JR: Species differences in bradykinin receptor-mediated responses of the airways. Autonomic Autocoid Pharmacol (2002) 22:3–16.
  • SANT'AMBROGIO G: Afferent pathways for the cough reflex. Bull. Eut: Physiopathol Respic (1987) 23:S19–S23.
  • HARGREAVES M, RAVI K, SENARATNE MP, KAPPAGODA CT: Responses of airway rapidly adapting receptors to bradykinin before and after administration of enalapril in rabbits. Cl/n. Sci. (1992) 83:399–407.
  • KAJEKAR R, PROUD D, MYERS AC, MEEKER SN, UNDEM BJ: Characterization of vagal afferent subtypes stimulated by bradykinin in guinea pig trachea. j. Pharmacol Exp. The]: (1999) 298:682–687.
  • CANNING BJ: Interactions between vagal afferent nerve subtypes mediating cough. Pulmon. Pharm. The]: (2002) 15:187–192.
  • UNDEM BJ, CARR MJ: Pharmacology of airway afferent nerve activity. Respic Res. (2001) 2:234–244.
  • FEATHERSTONE RL, PARRY JE, EVANS DM et al.: Mechanism of irritant-induced cough: studies with a kinin antagonist and a kallikrein inhibitor. Lung (1996) 174:269–275.
  • FOX AJ, LALLOO UG, BELVISI MG, BERNAREGGI M, CHUNG KF, BARNES PJ: Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nat. Med. (1996) 8:814–817.
  • QIU Z, LIU Q, GUO D, FU X: [The effect of bradykinin B2 receptor antagonist on cough reactivity in a sensitized guinea pig model]. Zhonghua Be He He Hu Xi Za Zhi (2002) 25:74-77. Chinese.
  • CHOUDRY NB, FULLER RW, PRIDE NB: Sensitivity of the human cough reflex: effect of inflammatory mediators prostaglandin E2, bradykinin, and histamine. Am. Rev Respir. Dis. (1989) 140:137–141.
  • BERMAN AR, TOGIAS AG, SKLOOT G, PROUD D: Allergen-induced hyperresponsiveness to bradykinin is more pronounced than that to methacholine. Appl. Physic] (1995) 78:1844–1852.
  • KATSUMATA U, SEKIZAWA K, UJIIE Y, SASAKI H, TAKISHIMA T: Bradykinin-induced cough reflex markedly increases in patients with cough associated with captopril and enalapril. Tohoku. j Exp. Med. (1991) 164:103–109.
  • SHIONOIRI H, TAKASAKI I, MINAMISAWA K et al.: Cough-challenge trial with a new angiotensin-converting enzyme inhibitor, imidapril. I Clin. Pharmacol (1998) 38:442–446.
  • KAMEI J, HUKUHARA T, KASUYA Y: Dopaminergic control of the cough reflex as demonstrated by the effects of apomorphine. Eur. Pharmacol (1987) 141:511–513.
  • O'CONNELL F: Central pathways for cough in man - unanswered questions. Pulmon. Pharm. Ther. (2002) 15:295–301.
  • NEWBOLD P, JACKSON DM, YOUNG A et al.: Dual D2 dopamine receptor and I32-adrenoceptor agonists for the modulation of sensory nerves in COPD. In: New Drugs M Asthma, Allergy and COPD. TT Hansel, PJ Barnes (Eds), Karger, Basel, Switzerland (2001):68–71.
  • BIRRELL MA, CRISPINO N, HELE DJ et al.: Effect of dopamine receptor agonist on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. Br. J. Pharmacol (2002) 136:620–628.
  • CELLI B, HALPIN D, HEPBURN R, BYRNES N, KEATING ET, GOLMAN M: Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study suing the breathlessness, cough and sputum scale (BCSS). Respir. Med (2003) 97:S35–S43.
  • IND PW, LAITINEN L, LAURSEN L etaL: Early clinical investigation of Viozan (sibenadet HC1), a novel D2 dopamine receptor, 132-adrenergic agonist for the treatment of chronic obstructive pulmonary disease symptoms. Repir. Mel (2003) 97:S9–S21.
  • LAURSEN LC, LINDQVIST A, HEPBURN T et al.: The role of the novel D2/32-agonist, Viozan (sibenadet HCL), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigation. Respir. Med. (2003) 97:S23–S33.
  • SANDERS-BUSH E, MAYER SE: 5-Hydroxytryptamine (serotonin) receptor agonist, and antagonist. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics (9th edi). JG Hardman, LE Limbird, PB Molinoff, RW Ruddon, AG Gilman (Eds), McGraw-Hill, New York, USA (1996):249–263.
  • KAMEI J, MORI T, IGARASHI H, KASUYA Y: Effects of 8-hydroxy 2 (cli N-propylamino)teralin, a selective agonist of 5-HT1A receptors, on the cough reflex in rats. Eur. Pharmacol (1991) 203:253–258.
  • STONE RA, WORSDELL YM, FULLER RW, BARNES PJ: Effects of 5-hydroxytryptamine and 5-hydroxytrophan infusion on the human cough reflex. I Appl. Physiol (1993) 74:396–401.
  • CAMBELL WB, HALUSHKA PV: Lipid-derived autacoids. In: Goodman and Gilman.'c The Pharmacological Basic of Therapeutics Oh edit). JG Hardman, LE Limbird, PB Molinoff, RW Ruddon, AG Gilman (Eds), McGraw-Hill, New York, USA (1996):601–616.
  • JOHNSON D, OSBORNE LM: Cough-variant asthma: a review of the clinical literature J. Asthma (1991) 28:85–90.
  • DICPINIGAITIS PV, DOBKIN JB, REICHEL J: Antitussive effect of leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. J. Asthma (2002) 39:291–297.
  • FUJIMURA M, KAMIO Y, KASAHARA K, BANDO T, HASHIMOTO T, MATSUDA T: Prostanoids and cough response to capsaicin in asthma and chronic bronchitis. Eur. Respir. J. (1995) 8:1499–1505.
  • UMEMURA K, NAKASHIMA M, SARUTA T: Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors. Life Sci. (1987) 60:1583–1588.
  • ADCOCK JJ, DOUGLAS GJ, GARABETTE M et al.: RSD-931, a novel antitussive agent acting on airway sensory nerves. Br. .1. Pharmacol (2003) 138:407–416.
  • LEE PCL, JAWAD MS, ECCLES R: Antitussive efficacy of dextromethorphan in cough associated with acute upper respiratory tract infection. J. Pharm. Pharmacol 52:1137-1142.
  • SCHROEDER K, FAHEY T: Systematic review of randomized controlled trials of over the counter cough medicines for acute cough in adults. Br. Med. .1. (2002) 324:329–331.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.